免疫腫瘍学の世界市場

• 英文タイトル:Global Market Study on Immuno-Oncology: Immune Checkpoint Inhibitors Segment Projected to be the Most Lucrative Segment by Therapy Type

Global Market Study on Immuno-Oncology: Immune Checkpoint Inhibitors Segment Projected to be the Most Lucrative Segment by Therapy Type「免疫腫瘍学の世界市場」(市場規模、市場予測)調査レポートです。• レポートコード:PMR-DC041
• 出版社/出版日:Persistence Market Research / 2019年9月25日
• レポート形態:英文、PDF、168ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Individual User(1名用)¥534,100 (USD4,900)▷ お問い合わせ
  Multi User(5名用)¥828,400 (USD7,600)▷ お問い合わせ
  Corporate User(企業用)¥1,155,400 (USD10,600)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査レポートでは、免疫腫瘍学の世界市場について調査・分析し、市場概要、市場力学、主要インクルージョン、治療法別(免疫チェックポイント阻害剤、免疫系モジュレーター、がんワクチン、腫瘍溶解性ウイルス、その他(免疫細胞療法など))分析、治療範囲別(黒色腫、肺がん、血液がん、腎細胞がん、前立腺がん、膀胱がん、その他のがん)分析、エンドユーザー別(病院、診療所、外来手術センター)分析、地域別(北米、ラテンアメリカ、ヨーロッパ、アジア太平洋、中東・アフリカ)分析、競合分析などを含め次の構成でお届け致します。

・エグゼクティブサマリー
・市場概要
・市場力学
・主要インクルージョン
・免疫腫瘍学の世界市場:治療法別(免疫チェックポイント阻害剤、免疫系モジュレーター、がんワクチン、腫瘍溶解性ウイルス、その他(免疫細胞療法など))
・免疫腫瘍学の世界市場:治療範囲別(黒色腫、肺がん、血液がん、腎細胞がん、前立腺がん、膀胱がん、その他のがん)
・免疫腫瘍学の世界市場:エンドユーザー別(病院、診療所、外来手術センター)
・免疫腫瘍学の世界市場:地域別(北米、ラテンアメリカ、ヨーロッパ、アジア太平洋、中東・アフリカ)
・競合分析

Persistence Market Research (PMR) recently published a market study on the global market for immune-oncology. The study provides detailed assessment on the key market dynamics, including drivers, trends, opportunities restraints, and detailed information about the immuno-oncology market structure. The market study presents exclusive information about how the immuno-oncology market will grow during the forecast period of 2019-2029.

Key indicators of market growth, which include Year-on-Year (Y-o-Y) growth of the market, and compounded annual growth rate (CAGR) are explained in PMR’s study in a comprehensive manner. This information can help readers understand the quantitative growth prospects of the immuno-oncology market during the forecast period.

The study is relevant for stakeholders in the immuno-oncology market, including immuno-oncology therapy manufacturers, suppliers, distributors, and investors, and can help them in developing appropriate strategies to grow in the market. Stakeholders in the immuno-oncology market, investors, industry experts, researchers, and journalists, as well as business researchers can leverage the information and data presented in PMR’s study.

The study also includes statistics as well as facts related to macro as well as microeconomic factors that are impacting developments in the market. It also offers actionable insights based on the future trends in the immuno-oncology market. Furthermore, small businesses and new entrants in the immuno-oncology market too can make use of the information presented in this study, based on which, they can make appropriate business decisions in order to gain momentum in the market.

Key Questions Answered in PMR’s Immuno-Oncology Market Report

Which regions will continue to remain the most profitable regional markets for immuno-oncology market players?
Which factors will induce a change in the demand for immuno-oncology therapy during the assessment period?
How will changing trends impact the immuno-oncology market?
How can market players capture the low-hanging opportunities in the immuno-oncology market in developed regions?
Which companies are leading the immuno-oncology market?
What are the winning strategies of stakeholders in the immuno-oncology market to upscale their position in this landscape?
Immuno-Oncology Market: Research Methodology

In PMR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the immuno-oncology market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure accuracy and reliability of the conclusions.

Secondary resources referred to analysts during the production of the immuno-oncology market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary resources and secondary resources acts as a validation from companies in the immuno-oncology market, and makes PMR’s projection on the growth prospects of the immuno-oncology market more accurate and reliable.

レポート目次

1. Executive Summary

1.1. Global Market Outlook

1.2. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusion and Exclusions

3. Market Dynamics

3.1. Macro-Economic Factors

3.2. Drivers

3.2.1. Supply Side Drivers

3.2.2. Demand Side Drivers

3.3. Restraints

3.4. Opportunities

3.5. Trends

4. Key Inclusion

4.1. Epidemiology Data, by Region

4.2. Regulatory Scenario

4.3. Patient Support Programs

4.4. Pipeline Snapshot

5. Global Immuno-Oncology Market Value Analysis 2014-2018 and Forecast, 2019-2029

5.1. Historical Market Value (US$ Mn) Analysis, 2014-2018

5.2. Current and Future Market Value (US$ Mn) Projections, 2019-2029

5.2.1. Y-o-Y Growth Trend Analysis

5.2.2. Absolute $ Opportunity Analysis

6. Global Immuno-Oncology Market Analysis 2014-2018 and Forecast 2019-2029, by Therapy

6.1. Introduction / Key Findings

6.2. Historical Market Size (US$ Mn) Analysis By Therapy, 2014-2018

6.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Therapy, 2019 – 2029

6.3.1. Immune Checkpoint Inhibitors

6.3.1.1. PD-1

6.3.1.2. PD-L1

6.3.1.3. CTLA-4

6.3.2. Immune System Modulators

6.3.3. Cancer Vaccines

6.3.4. Oncolytic Virus

6.3.5. Others (immune cell therapy, etc.)

6.4. Market Attractiveness Analysis By Therapy

7. Global Immuno-Oncology Market Analysis 2014-2018 and Forecast 2019-2029, by Therapeutic Area

7.1. Introduction / Key Findings

7.2. Historical Market Size (US$ Mn) Analysis By Therapeutic Area, 2014-2018

7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Therapeutic Area, 2019 – 2029

7.3.1. Melanoma

7.3.2. Lung Cancer

7.3.3. Blood Cancers

7.3.4. Renal Cell Carcinoma

7.3.5. Prostate Cancer

7.3.6. Bladder Cancer

7.3.7. Other Cancers

7.4. Market Attractiveness Analysis By Therapeutic Area

8. Global Immuno-Oncology Market Analysis 2014-2018 and Forecast 2019-2029, by End User

8.1. Introduction / Key Findings

8.2. Historical Market Size (US$ Mn) Analysis By End User, 2014-2018

8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2019 – 2029

8.3.1. Hospitals

8.3.2. Clinics

8.3.3. Ambulatory Surgical Centers

8.4. Market Attractiveness Analysis By End User

9. Global Immuno-Oncology Market Analysis 2014-2018 and Forecast 2019-2029, by Region

9.1. Introduction

9.2. Historical Market Size (US$ Mn) Analysis By Region, 2014-2018

9.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2019 – 2029

9.3.1. North America

9.3.2. Latin America

9.3.3. Europe

9.3.4. Asia-Pacific

9.3.5. Middle East & Africa

9.4. Market Attractiveness Analysis By Region

10. North America Immuno-Oncology Market Analysis 2014-2018 and Forecast 2019-2029

10.1. Introduction

10.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018

10.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019-2029

10.3.1. By Country

10.3.1.1. U.S.

10.3.1.2. Canada

10.3.2. By Therapy

10.3.3. By Therapeutic Area

10.3.4. By End User

10.4. Market Attractiveness Analysis

10.5. Key Impact Analysis

11. Latin America Immuno-Oncology Market Analysis 2014-2018 and Forecast 2019-2029

11.1. Introduction

11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018

11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019-2029

11.3.1. By Country

11.3.1.1. Brazil

11.3.1.2. Mexico

11.3.1.3. Rest of Latin America

11.3.2. By Therapy

11.3.3. By Therapeutic Area

11.3.4. By End User

11.4. Market Attractiveness Analysis

11.5. Key Impact Analysis

12. Europe Immuno-Oncology Market Analysis 2014-2018 and Forecast 2019-2029

12.1. Introduction

12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018

12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019-2029

12.3.1. By Country

12.3.1.1. Germany

12.3.1.2. U.K.

12.3.1.3. France

12.3.1.4. Italy

12.3.1.5. Spain

12.3.1.6. Rest of Europe

12.3.2. By Therapy

12.3.3. By Therapeutic Area

12.3.4. By End User

12.4. Market Attractiveness Analysis

12.5. Key Impact Analysis

13. Asia-Pacific Immuno-Oncology Market Analysis 2014-2018 and Forecast 2019-2029

13.1. Introduction

13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018

13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019-2029

13.3.1. By Country

13.3.1.1. Japan

13.3.1.2. South Korea

13.3.1.3. Australia & New Zealand

13.3.1.4. China

13.3.1.5. Rest of Asia-Pacific

13.3.2. By Therapy

13.3.3. By Therapeutic Area

13.3.4. By End User

13.4. Market Attractiveness Analysis

13.5. Key Impact Analysis

14. Middle East and Africa Immuno-Oncology Market Analysis 2014-2018 and Forecast 2019-2029

14.1. Introduction

14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018

14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019-2029

14.3.1. By Country

14.3.1.1. GCC Countries

14.3.1.2. South Africa

14.3.1.3. Rest of MEA

14.3.2. By Therapy

14.3.3. By Therapeutic Area

14.3.4. By End User

14.4. Market Attractiveness Analysis

14.5. Key Impact Analysis

15. Competition Analysis

15.1. Company Share Analysis

15.2. Competition Dashboard

15.3. Competition Deep Dive

15.3.1. Amgen, Inc.

15.3.1.1. Company Overview

15.3.1.2. Segment Overview

15.3.1.3. TherapyOfferings

15.3.1.4. Financial Analysis

15.3.1.5. Key Developments

15.3.1.6. Strategy Overview

15.3.2. AstraZeneca Plc

15.3.2.1. Company Overview

15.3.2.2. Segment Overview

15.3.2.3. TherapyOfferings

15.3.2.4. Financial Analysis

15.3.2.5. Key Developments

15.3.2.6. Strategy Overview

15.3.3. Bristol-Myers Squibb Company

15.3.3.1. Company Overview

15.3.3.2. Segment Overview

15.3.3.3. TherapyOfferings

15.3.3.4. Financial Analysis

15.3.3.5. Key Developments

15.3.3.6. Strategy Overview

15.3.4. F. Hoffmann-La Roche Ltd.

15.3.4.1. Company Overview

15.3.4.2. Segment Overview

15.3.4.3. TherapyOfferings

15.3.4.4. Financial Analysis

15.3.4.5. Key Developments

15.3.4.6. Strategy Overview

15.3.5. Merck & Co., Inc.

15.3.5.1. Company Overview

15.3.5.2. Segment Overview

15.3.5.3. TherapyOfferings

15.3.5.4. Financial Analysis

15.3.5.5. Key Developments

15.3.5.6. Strategy Overview

15.3.6. Novartis AG

15.3.6.1. Company Overview

15.3.6.2. Segment Overview

15.3.6.3. TherapyOfferings

15.3.6.4. Financial Analysis

15.3.6.5. Key Developments

15.3.6.6. Strategy Overview

15.3.7. Pfizer Inc.

15.3.7.1. Company Overview

15.3.7.2. Segment Overview

15.3.7.3. TherapyOfferings

15.3.7.4. Financial Analysis

15.3.7.5. Key Developments

15.3.7.6. Strategy Overview

15.3.8. Sanofi.

15.3.8.1. Company Overview

15.3.8.2. Segment Overview

15.3.8.3. TherapyOfferings

15.3.8.4. Financial Analysis

15.3.8.5. Key Developments

15.3.8.6. Strategy Overview

16. Assumptions and Acronyms Used

17. Research Methodology

List of Tables

Table 01: Immuno-Oncology Market Value (US$ Mn) Growth Comparison
Table 02: Global Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapy
Table 03: Global Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapeutic Area
Table 04: Global Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By End User
Table 05: Global Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Region
Table 06: North America Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Country
Table 07: North America Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapy
Table 08: North America Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapeutic Area
Table 09: North America Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By End User
Table 10: Latin America Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Country
Table 11: Latin America Immuno-Oncology Market Size(US$Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapy
Table 12: Latin America Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapeutic Area
Table 13: Latin America Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By End User
Table 14: Europe Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Country
Table 15: Europe Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapy
Table 16: Europe Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapeutic Area
Table 17: Europe Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By End User
Table 18: Asia Pacific Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Country
Table 19: Asia Pacific Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapy
Table 20: Asia Pacific Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapeutic Area
Table 21: Asia Pacific Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By End User
Table 22: Middle East and Africa Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Country
Table 23: Middle East and Africa Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapy
Table 24: Middle East and Africa Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapeutic Area
Table 25: Middle East and Africa Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By End User




• 英文レポート名:Global Market Study on Immuno-Oncology: Immune Checkpoint Inhibitors Segment Projected to be the Most Lucrative Segment by Therapy Type
• 日本語訳:免疫腫瘍学の世界市場
• レポートコード:PMR-DC041お問い合わせ(見積依頼・ご注文・質問)